David A. Siegel Kezar Life Sciences, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,402,900 shares of KZR stock, worth $9.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,402,900

Previous 1,237,600 13.36%

Holding current value

$9.15 Million

Previous $742,000 45.55%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.53 - $0.77 $87,609 - $127,281	165,300 Added 13.36%	1,402,900 $1.08 Million
Q2 2024 Aug 14, 2024	BUY	$0.6 - $0.92 $3,480 - $5,336	5,800 Added 0.47%	1,237,600 $742,000
Q1 2024 May 15, 2024	SELL	$0.8 - $1.05 $72,400 - $95,025	-90,500 Reduced 6.84%	1,231,800 $1.11 Million
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.15 $469,728 - $750,260	652,400 Added 97.39%	1,322,300 $1.26 Million
Q3 2023 Nov 14, 2023	SELL	$1.08 - $2.54 $223,992 - $526,796	-207,400 Reduced 23.64%	669,900 $797,000
Q2 2023 Aug 14, 2023	BUY	$2.31 - $3.06 $812,427 - $1.08 Million	351,700 Added 66.91%	877,300 $2.15 Million
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $456,667 - $1.07 Million	145,900 Added 38.43%	525,600 $1.65 Million
Q4 2022 Feb 14, 2023	SELL	$6.39 - $8.8 $594,270 - $818,400	-93,000 Reduced 19.67%	379,700 $2.67 Million
Q3 2022 Nov 14, 2022	SELL	$7.99 - $10.75 $1.45 Million - $1.96 Million	-182,100 Reduced 27.81%	472,700 $4.07 Million
Q2 2022 Aug 15, 2022	BUY	$4.58 - $17.13 $711,274 - $2.66 Million	155,300 Added 31.09%	654,800 $5.42 Million
Q1 2022 May 16, 2022	SELL	$12.3 - $18.33 $151,290 - $225,458	-12,300 Reduced 2.4%	499,500 $8.3 Million
Q4 2021 Feb 14, 2022	BUY	$7.44 - $16.72 $1.71 Million - $3.85 Million	230,100 Added 81.68%	511,800 $8.56 Million
Q3 2021 Nov 15, 2021	BUY	$4.85 - $9.73 $335,135 - $672,343	69,100 Added 32.5%	281,700 $2.43 Million
Q2 2021 Aug 16, 2021	SELL	$4.93 - $6.46 $190,791 - $250,002	-38,700 Reduced 15.4%	212,600 $1.15 Million
Q1 2021 May 17, 2021	SELL	$5.24 - $6.99 $184,972 - $246,747	-35,300 Reduced 12.32%	251,300 $1.5 Million
Q4 2020 Feb 16, 2021	SELL	$4.77 - $6.58 $69,642 - $96,068	-14,600 Reduced 4.85%	286,600 $1.5 Million
Q3 2020 Nov 16, 2020	BUY	$4.36 - $5.5 $875,924 - $1.1 Million	200,900 Added 200.3%	301,200 $1.46 Million
Q2 2020 Aug 14, 2020	BUY	$3.6 - $7.75 $130,320 - $280,550	36,200 Added 56.47%	100,300 $520,000
Q1 2020 May 15, 2020	BUY	$2.77 - $5.75 $37,949 - $78,775	13,700 Added 27.18%	64,100 $279,000
Q4 2019 Feb 14, 2020	SELL	$2.5 - $4.26 $32,500 - $55,380	-13,000 Reduced 20.5%	50,400 $202,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $7.58 $190,200 - $480,572	63,400 New	63,400 $208,000

Others Institutions Holding KZR

# of Institutions

Shares Held

38.4M

Call Options Held

13.8K

Put Options Held

600

View Full List

About Kezar Life Sciences, Inc.

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

More about KZR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account